1 |
Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
|
2 |
Zafiropoulos A, Crikas N, Passam AM, Spandidos DA (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet, 41,59.
DOI
|
3 |
Kontogianni P, Zambirinis CP, Theodoropoulos G, et al (2013). The impact of the stromal cell-derived factor-1-3'A and E-selectin S128R polymorphisms on breast cancer. Mol Biol Rep, 40, 43-50.
DOI
ScienceOn
|
4 |
Kruszyna L, Lianeri M, Rubis B, et al (2010). CXCL12-3' G801A polymorphism is not a risk factor for breast cancer. DNA Cell Biol, 29, 423-7.
DOI
ScienceOn
|
5 |
Lin GT, Tseng HF, Yang CH, et al (2009). Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS, 13, 165-72.
DOI
|
6 |
Ma XY, Jin Y, Sun HM, et al (2012). CXCL12 G801A polymorphism contributes to cancer susceptibility: a metaanalysis. Cell Mol Biol, 58, 1702-8.
|
7 |
Razmkhah M, Doroudchi M, Ghayumi SM, et al (2005). Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer, 49, 311-5.
DOI
ScienceOn
|
8 |
Razmkhah M, Talei AR, Doroudchi M, et al (2005). Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett, 225, 261-6.
DOI
ScienceOn
|
9 |
Shen W, Cao X, Xi L, Deng L (2012). CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 2039-44.
DOI
|
10 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
11 |
Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 470-1.
|
12 |
Thakkinstian A, McElduff P, D'Este C, et al (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306.
DOI
ScienceOn
|
13 |
de Oliveira KB, Oda JM, Voltarelli JC, et al (2009). CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal, 23, 387-93.
DOI
ScienceOn
|
14 |
Cochran WG (1968). The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics, 24, 295-313.
DOI
ScienceOn
|
15 |
de Oliveira KB, Guembarovski RL, Guembarovski AM, et al (2013). CXCL12, CXCR4 and IFNgamma genes expression: implications for proinflammatory microenvironment of breast cancer. Clin Exp Med, 13, 211-9.
DOI
ScienceOn
|
16 |
de Oliveira KB, Guembarovski RL, Oda JM, et al (2011). CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine, 55, 260-5.
DOI
ScienceOn
|
17 |
Desantis C, Ma J, Bryan L, Jemal A (2014). Breast cancer statistics, 2013. CA Cancer J Clin, 64, 52-62.
DOI
ScienceOn
|
18 |
Dimberg J, Hugander A, Lofgren S, Wagsater D. (2007). Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med, 19, 11-5.
|
19 |
Donnelly TT, Khater AH, Al-Bader SB, et al (2013). Arab women's breast cancer screening practices: a literature review. Asian Pac J Cancer Prev, 14, 4519-28.
DOI
ScienceOn
|
20 |
Gong H, Tan M, Wang Y, et al (2012). The CXCL12 G801A polymorphism and cancer risk: evidence from 17 casecontrol studies. Gene, 509, 228-31.
DOI
ScienceOn
|
21 |
Hinton CV, Avraham S, Avraham HK (2010). Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis, 27, 97-105.
DOI
|
22 |
Hassan S, Baccarelli A, Salvucci O, and Basik M (2008). Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res, 14, 446-54.
DOI
ScienceOn
|
23 |
Chuang LY, Chang HW, Lin MC, Yang CH (2012). Chaotic particle swarm optimization for detecting SNP-SNP interactions for CXCL12-related genes in breast cancer prevention. Eur J Cancer Prev, 21, 336-42.
DOI
|